Literature DB >> 32399274

Magnetic resonance imaging for preoperative staging of pancreatic cancer based on the 8th edition of AJCC guidelines.

Yan Deng1, Bing Ming2, Jia-Long Wu1, Ting Zhou1, Shi-Yong Zhang2, Yong Chen1, Chuan Lan3, Xiao-Ming Zhang1.   

Abstract

BACKGROUND: Preoperative staging of pancreatic cancer determines the choice of treatment. Magnetic resonance imaging (MRI) plays an important role in preoperative staging of pancreatic cancer. The American Joint Committee on Cancer (AJCC) TNM staging system was revised to its 8th version in 2016, there has been no report correlating the 8th edition of the AJCC TNM staging with preoperative MRI examinations and pathological findings. The purpose of our study is to determine the staging accuracy and evaluate the resectability by using MRI about pancreatic cancer compared with intraoperative or pathological findings according to the 8th edition of the AJCC TNM staging system.
METHODS: One hundred thirty-two patients with a pathological diagnosis of pancreatic cancer who underwent preoperative MRI were identified. The clinical data, MRI findings and pathological findings were analyzed. Preoperative MRI staging and resectability evaluation were compared with pathological findings. The accuracy of MRI for preoperative T and N staging was evaluated, and the sensitivity, specificity and accuracy of MRI in evaluating the resectability were assessed. All the staging and resectability assessments were according to the 8th edition of the AJCC TNM staging system.
RESULTS: Analysis showed that the accuracy of MRI for evaluation of the T and N stages was 82.6% (109/132) and 74.2% (98/132), respectively. The sensitivity and specificity of MRI in assessing the resectability were 94.2% and 71.4%, respectively. Integrating the 8th edition of the AJCC TNM stage, no significant differences were identified between the preoperative MRI and pathological results for the staging of pancreatic cancer (P=0.805).
CONCLUSIONS: MRI is highly accurate for T staging and moderately accurate for N staging. MRI provides important preoperative evaluation of the stage and resectability of pancreatic cancer based on the 8th edition of the AJCC TNM staging system. 2020 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Pancreatic cancer; magnetic resonance imaging (MRI); resectability; staging

Year:  2020        PMID: 32399274      PMCID: PMC7212112          DOI: 10.21037/jgo.2020.03.06

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  31 in total

1.  Preoperative assessment of para-aortic lymph node metastasis in patients with pancreatic cancer.

Authors:  Hisashi Imai; Ryuichiro Doi; Hiroyuki Kanazawa; Naoko Kamo; Masayuki Koizumi; Toshihiko Masui; Yasuhiro Iwanaga; Yoshiya Kawaguchi; Yasutsugu Takada; Hiroyoshi Isoda; Shinji Uemoto
Journal:  Int J Clin Oncol       Date:  2010-03-16       Impact factor: 3.402

2.  Preoperative assessment of pancreatic tumors using magnetic resonance imaging, endoscopic ultrasonography, positron emission tomography and laparoscopy.

Authors:  Ivan Borbath; Bernard E Van Beers; Max Lonneux; Daniel Schoonbroodt; André Geubel; Jean-François Gigot; Pierre H Deprez
Journal:  Pancreatology       Date:  2005-08-18       Impact factor: 3.996

3.  Prediction of vascular involvement and resectability by multidetector-row CT versus MR imaging with MR angiography in patients who underwent surgery for resection of pancreatic ductal adenocarcinoma.

Authors:  Jeong Kyong Lee; Ah Young Kim; Pyo Nyun Kim; Moon-Gyu Lee; Hyun Kwon Ha
Journal:  Eur J Radiol       Date:  2008-12-13       Impact factor: 3.528

4.  Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma.

Authors:  Chen Liu; He Cheng; Kaizhou Jin; Meng Guo; Yu Lu; Zhengshi Wang; Chao Yang; Jiang Long; Quanxing Ni; Xianjun Yu; Guopei Luo
Journal:  Pancreas       Date:  2018-07       Impact factor: 3.327

5.  Imaging for pancreatic ductal adenocarcinoma.

Authors:  Natally Horvat; Davinia E Ryan; Maria D LaGratta; Pari M Shah; Richard Kinh Do
Journal:  Chin Clin Oncol       Date:  2017-12

6.  Lymph node size and metastatic infiltration in adenocarcinoma of the pancreatic head.

Authors:  K L Prenzel; A H Hölscher; D Vallböhmer; U Drebber; C A Gutschow; S P Mönig; D L Stippel
Journal:  Eur J Surg Oncol       Date:  2010-07-01       Impact factor: 4.424

Review 7.  Evaluation of focal pancreatic masses: comparison of mangafodipir-enhanced MR imaging and contrast-enhanced helical CT.

Authors:  Wolfgang Schima; Reinhold Függer
Journal:  Eur Radiol       Date:  2002-07-12       Impact factor: 5.315

8.  Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography.

Authors:  Antonio Soriano; Antoni Castells; Carmen Ayuso; Juan Ramón Ayuso; Maria Teresa de Caralt; Maria Angels Ginès; Maria Isabel Real; Rosa Gilabert; Llorenç Quintó; Antoni Trilla; Faust Feu; Xavier Montanyà; Laureano Fernández-Cruz; Salvador Navarro
Journal:  Am J Gastroenterol       Date:  2004-03       Impact factor: 10.864

9.  Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT.

Authors:  Wolfgang Schima; Reinhold Függer; Ewald Schober; Claudia Oettl; Peter Wamser; Florian Grabenwöger; J Mark Ryan; Gottfried Novacek
Journal:  AJR Am J Roentgenol       Date:  2002-09       Impact factor: 3.959

10.  Equipping the American Joint Committee on Cancer staging for resectable pancreatic ductal adenocarcinoma with tumor grade: a recursive partitioning analysis.

Authors:  Yu-Tong Chen; Ze-Ping Huang; Zhi-Wei Zhou; Ming-Ming He
Journal:  Med Oncol       Date:  2016-10-11       Impact factor: 3.064

View more
  1 in total

Review 1.  Magnetic Fields and Cancer: Epidemiology, Cellular Biology, and Theranostics.

Authors:  Massimo E Maffei
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.